New hope for Hard-to-Treat myeloma: targeted drug shows promise
NCT ID NCT03525678
First seen Sep 30, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This study tested an experimental drug called belantamab mafodotin in 221 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. Participants received one of two doses of the drug by IV infusion. The main goal was to see how many people's tumors shrank or disappeared. The drug is designed to target and kill myeloma cells while limiting harm to healthy cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
New Haven, Connecticut, 06510, United States
-
GSK Investigational Site
Atlanta, Georgia, 30322, United States
-
GSK Investigational Site
Atlanta, Georgia, 30342, United States
-
GSK Investigational Site
Chicago, Illinois, 60612, United States
-
GSK Investigational Site
Chicago, Illinois, 60637, United States
-
GSK Investigational Site
Indianapolis, Indiana, 46202, United States
-
GSK Investigational Site
Fairway, Kansas, 66205, United States
-
GSK Investigational Site
Baton Rouge, Louisiana, 70121, United States
-
GSK Investigational Site
Baltimore, Maryland, 21201, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Rochester, Minnesota, 55905, United States
-
GSK Investigational Site
New York, New York, 10029, United States
-
GSK Investigational Site
New York, New York, 10065, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
-
GSK Investigational Site
Columbus, Ohio, 43210, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Nashville, Tennessee, 37232, United States
-
GSK Investigational Site
Houston, Texas, 77030, United States
-
GSK Investigational Site
Salt Lake City, Utah, 84112, United States
-
GSK Investigational Site
Seattle, Washington, 98109, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Woodville, South Australia, 5011, Australia
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Melbourne, Victoria, 3004, Australia
-
GSK Investigational Site
Calgary, Alberta, T2N 4N2, Canada
-
GSK Investigational Site
Winnipeg, Manitoba, R3E 0V9, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G 2M9, Canada
-
GSK Investigational Site
Lille, 59037, France
-
GSK Investigational Site
Nantes, 44093, France
-
GSK Investigational Site
Paris, 75010, France
-
GSK Investigational Site
Pessac, 33600, France
-
GSK Investigational Site
Pierre-Bénite, 69495, France
-
GSK Investigational Site
Toulouse, 31059, France
-
GSK Investigational Site
Dresden, 01307, Germany
-
GSK Investigational Site
Hanover, 30625, Germany
-
GSK Investigational Site
Koblenz, 56068, Germany
-
GSK Investigational Site
Schwerin, 19049, Germany
-
GSK Investigational Site
Tübingen, 72076, Germany
-
GSK Investigational Site
Würzburg, 97080, Germany
-
GSK Investigational Site
Aviano PN, 33081, Italy
-
GSK Investigational Site
Parma, 43126, Italy
-
GSK Investigational Site
Rionero in Vulture PZ, 85028, Italy
-
GSK Investigational Site
Torino, 10126, Italy
-
GSK Investigational Site
Badalona, 08916, Spain
-
GSK Investigational Site
Barcelona, 08036, Spain
-
GSK Investigational Site
Granada, 18014, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Madrid, 28223, Spain
-
GSK Investigational Site
Murcia, 30008, Spain
-
GSK Investigational Site
PamplonaNavarra, 31008, Spain
-
GSK Investigational Site
Salamanca, 37007, Spain
-
GSK Investigational Site
Valencia, 46017, Spain
-
GSK Investigational Site
Birmingham, B9 5SS, United Kingdom
-
GSK Investigational Site
Bournemouth, BH7 7DW, United Kingdom
-
GSK Investigational Site
London, NW1 2BU, United Kingdom
-
GSK Investigational Site
Nottingham, NG5 1PB, United Kingdom
-
GSK Investigational Site
Oxford, OX3 7LE, United Kingdom
-
GSK Investigational Site
Stoke-on-Trent, ST4 6QG, United Kingdom
-
GSK Investigational Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.